title: Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs.
abstract: OBJECTIVE
  This study assessed the cardiovascular effects of gadoversetamide and other gadolinium chelates administered at high rates of injection.
  
  
  METHODS
  Anesthetized beagles were instrumented to record the electrocardiogram and to measure arterial blood pressure. In part 1, each animal was injected with gadoversetamide at rates of 1.0, 3.0, and 10 mL/s. In part 2, each animal was injected with gadoversetamide, gadopentetate dimeglumine, gadodiamide, and gadoteridol at a dose of 0.6 mmol/kg delivered at a rate of 3.0 mL/s.
  
  
  RESULTS
  Intravenous administration of gadoversetamide caused transient decreases in both heart rate and blood pressure. The rate of injection did not affect the magnitude of the heart rate or blood pressure changes. Administration of gadoversetamide, gadopentetate dimeglumine, and gadodiamide elicited equivalent changes in cardiovascular function. Injection of gadoteridol caused a similar degree of hypotension, but the changes lasted longer.
  
  
  CONCLUSIONS
  Rapid administration of gadoversetamide caused no potentiation in cardiovascular changes. Our data support the initiation of a clinical trial to demonstrate the safety of rapidly administering gadoversetamide with the use of a power injector.
authors.affiliation: Mallinckrodt Inc. St. Louis, MO 63134, USA. jhwible@mkg.com
authors.forename: J H
authors.initials: JH
authors.lastname: Wible
authors.forename: K P
authors.initials: KP
authors.lastname: Galen
authors.forename: J K
authors.initials: JK
authors.lastname: Wojdyla
mesh_terms: D000758:Anesthesia; D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects*; D003287:Contrast Media / Q000008:administration & dosage*; D004285:Dogs; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000008:administration & dosage; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D007275:Injections, Intravenous / Q000379:methods; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA; C112666:gadoversetamide